ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd (TLSA)

1.07
0.2239
(26.46%)
Closed September 18 4:00PM
1.05
-0.02
(-1.87%)
After Hours: 7:28PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
1.05
Bid
1.04
Ask
1.05
Volume
506,508
0.8885 Day's Range 1.11
0.00 52 Week Range 0.00
Previous Close
0.8461
Open
0.8885
Last Trade
5
@
1.05
Last Trade Time
Average Volume (3m)
-
Financial Volume
$ 536,256
VWAP
1.0587

TLSA Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
OMEXOdyssey Marine Exploration Inc
$ 1.39
(180.07%)
328.97M
PRTGPortage Biotech Inc
$ 9.7581
(115.41%)
51.55M
APLTApplied Therapeutics Inc
$ 7.86
(69.03%)
51.67M
XCHXCHG Ltd
$ 18.40
(65.77%)
1.26M
WBUYWeBuy Global Ltd
$ 0.1867
(60.95%)
248.03M
GLMDGalmed Pharmaceuticals Ltd
$ 6.8501
(-54.64%)
5.79M
KAKineta Inc
$ 0.5691
(-31.35%)
530.66k
DTSSDatasea Inc
$ 2.07
(-29.59%)
1.28M
CBUSCibus Inc
$ 3.595
(-28.95%)
2.25M
BFIBurgerFi International Inc
$ 0.1705
(-26.98%)
16.23M
OMEXOdyssey Marine Exploration Inc
$ 1.39
(180.07%)
328.97M
NVDANVIDIA Corporation
$ 113.37
(-1.92%)
310.35M
WBUYWeBuy Global Ltd
$ 0.1867
(60.95%)
248.03M
SQQQProShares UltraPro Short QQQ
$ 8.40
(1.45%)
200.73M
LUNRIntuitive Machines Inc
$ 7.4512
(37.99%)
141.86M

TLSA Discussion

View Posts
Monksdream Monksdream 2 weeks ago
TLSA under $2
👍️0
glenn1919 glenn1919 1 month ago
TLSA.........................https://stockcharts.com/h-sc/ui?s=TLSA&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 1 month ago
TLSA...FULL OUT WEEKLY BREAK OUT!!!!
👍️0
TrendTrade2016 TrendTrade2016 1 month ago
TLSA...NEXT BIO BEAST READY TO FLY, NOT A BETTER CHART OUT THERE
👍️0
Monksdream Monksdream 2 months ago
TLSA 10Q expected JULY8
👍️0
Monksdream Monksdream 3 months ago
TLSA 10Q expected July 1
👍️0
Monksdream Monksdream 3 months ago
TLSA 10Q expected Monday 6/24
👍️0
Monksdream Monksdream 7 months ago
TLSA new 52 week low

👍️0
mfayman mfayman 11 months ago
Alot of room here
👍️0
mfayman mfayman 11 months ago
The 9s + breakout coming
👍️0
mfayman mfayman 11 months ago
Green day!! Volumes been consistent getting into a groove here
👍️0
Cameo Brien Cameo Brien 11 months ago
https://newsdirect.com/news/tiziana-life-sciences-reports-six-month-pet-scan-results-for-ms-patients-545441035
👍️ 1
Ryguy008 Ryguy008 11 months ago
Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment https://www.globenewswire.com/news-release/2023/10/18/2762186/0/en/Tiziana-Life-Sciences-Announces-Allowance-By-FDA-For-At-Home-Dosing-Of-Intranasal-Foralumab-For-Multiple-Sclerosis-Treatment.html

$TLSA
👍️0
Cameo Brien Cameo Brien 11 months ago
News

https://marketwirenews.com/news-releases/tiziana-life-sciences-announces-allowance-by-fda-for-8463755861297756.html
👍️0
Cameo Brien Cameo Brien 11 months ago
https://marketwirenews.com/articles/tiziana-life-sciences-plc-nasdaq-tlsa-short-squeeze--mwn-news-4013.html
👍️0
Cameo Brien Cameo Brien 11 months ago
Easy imo
👍️0
Cameo Brien Cameo Brien 11 months ago
Gm all
👍️0
Anita Dump Anita Dump 11 months ago
coffee and DD
👍️0
Anita Dump Anita Dump 11 months ago
good setup to pop from here
👍️0
Anita Dump Anita Dump 11 months ago
under the radar $TLSA
👍️0
Anita Dump Anita Dump 11 months ago
$1 yup
👍️0
mfayman mfayman 11 months ago
Next stop 1$ +
👍️0
Anita Dump Anita Dump 11 months ago
im in
👍️0
Cameo Brien Cameo Brien 11 months ago
Same here
👍️0
Ryguy008 Ryguy008 11 months ago
$TLSA keeping an eye here
👍️0
mfayman mfayman 11 months ago
Big week ahead!!
👍️0
mfayman mfayman 11 months ago
Nice volume today!!!
👍️0
elmasry elmasry 11 months ago
I am worried about the same thing because i received multiple emails last night about this stock which an indication there might be doing an offering
👍️0
Cameo Brien Cameo Brien 11 months ago
Let's get it
👍️0
mfayman mfayman 11 months ago
Thinking so ! Once we break 9s we might fly
👍️0
Anita Dump Anita Dump 11 months ago
room to move up some?
👍️0
Cameo Brien Cameo Brien 11 months ago
Hmm
👍️0
mfayman mfayman 11 months ago
Most definitely!!?
👍️0
Anita Dump Anita Dump 11 months ago
overdue?
👍️0
Cameo Brien Cameo Brien 11 months ago
Interested here
👍️0
mfayman mfayman 11 months ago
When .9s fall were gonna start moving fast
👍️0
Anita Dump Anita Dump 11 months ago
what does this show?
👍️0
mfayman mfayman 11 months ago
Looking up here $$ volumes been getting juicy
👍️0
Cameo Brien Cameo Brien 11 months ago
What we have here
👍️0
Monksdream Monksdream 1 year ago
Not going to zero but there will be a capital raise
👍️0
TheFinalCD TheFinalCD 1 year ago
https://finviz.com/quote.ashx?t=TLSA&ty=c&ta=1&p=d

https://dilutiontracker.com/app/search/TLSA?a=dbb88c
👍️0
subslover subslover 1 year ago
NEWS
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
Foralumab to advance into Phase 2 human clinical trials using the world’s only fully human intranasal anti-CD3 monoclonal antibody
Trial to be overseen by Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System
NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for intranasal foralumab to be studied in Alzheimer's disease. Foralumab could be a potentially groundbreaking treatment for Alzheimer’s disease, given it targets the disease’s underlying pathology by addressing the resulting neuroinflammation caused by the accumulation of toxic proteins in the brain.

Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences, stated, "The IND clearance is a significant milestone for Tiziana that highlights the strength and the therapeutic potential of foralumab. We are deeply committed to advancing the field of neurodegenerative diseases and bringing much-needed relief to patients suffering from Alzheimer's with a novel therapeutic approach. We are thrilled to have reached this critical juncture and are eager to move forward with the necessary trials to evaluate the effectiveness of foralumab in Alzheimer’s disease in combination with an FDA approved therapy or as a single agent."

Professor Howard L. Weiner, the Robert L. Kroc Professor of Neurology at the Harvard Medical School, Director and Founder of the Partners Multiple Sclerosis Center and Co-Director of the Center for Neurologic Diseases at Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System, added "The IND clearance is a significant step forward in the fight against Alzheimer's disease. Foralumab shows great promise in targeting the pathological hallmarks of the disease, and I am optimistic about its potential to offer a breakthrough treatment option for patients suffering from this devastating condition. I look forward to witnessing the progress of this important therapy."

About Foralumab

Activated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. Intranasal foralumab Phase 2 trials are expected to start in the third quarter of 2023 in patients with non-active SPMS. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of inflammatory human diseases.1

About Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

For further inquiries:

Tiziana Life Sciences Ltd

Paul Spencer, Business Development and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

Investors:
Irina Koffler
LifeSci Advisors, LLC
+1 646 970 4681
ikoffler@lifesciadvisors.com

1 https://www.pnas.org/doi/10.1073/pnas.2220272120

https://www.globenewswire.com/newsroom/ti?nf=ODg5NDQ4MCM1NzU1MjUzIzIxMjM4ODU=
https://ml.globenewswire.com/media/NzQzZDc4NjEtNTBmMS00OTU0LWFlMDctYzRhNzA0MTNmYmJmLTExMzU0NTY=/tiny/Tiziana-Life-Sciences-Plc.png

Source: Tiziana Life Sciences Ltd.
👍️0
The Night Stalker The Night Stalker 3 years ago
https://www.stockscores.com/chart.asp?TickerSymbol=%20tlsa&TimeRange=365&Interval=w&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=100&Indicator1=AccDist&Indicator2=StochRSI&Indicator3=CMF&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen
👍️0
The Night Stalker The Night Stalker 3 years ago
https://www.stockscores.com/chart.asp?TickerSymbol=%20tlsa&TimeRange=365&Interval=w&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=100&Indicator1=AccDist&Indicator2=StochRSI&Indicator3=CMF&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen
👍️0
The Night Stalker The Night Stalker 3 years ago
https://www.stockscores.com/chart.asp?TickerSymbol=%20tlsa&TimeRange=365&Interval=w&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=100&Indicator1=AccDist&Indicator2=StochRSI&Indicator3=CMF&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen
👍️0
The Night Stalker The Night Stalker 3 years ago
https://www.stockscores.com/chart.asp?TickerSymbol=%20tlsa&TimeRange=365&Interval=w&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=100&Indicator1=AccDist&Indicator2=StochRSI&Indicator3=CMF&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen
👍️0
Lanceroni Lanceroni 3 years ago
Know what you own or should own.
$TLSA deals in monoclonal medication and has a phase 2 trial using said against Covid-19.

1. This is a bonus play for monoclonal medication and it's being used for many other diseases, but it also works against Covid.

2. The U.K. (where $TLSA is listed as #TILS) has announced that they want to BE USING MONOCLONAL MEDICATION against Covid BY THE FALL. This is almost definitely a $TLSA play. Buying at these levels is an absolute no brainer.
👍️0
Crusader Crusader 4 years ago
$9.50 target?

Consensus Rating: Buy
Consensus Price Target: $9.50
Forecasted Upside: 134.57 %
Number of Analysts: 2
Breakdown:
0 Sell Ratings
0 Hold Ratings
2 Buy Ratings
0 Strong Buy Ratings

$4.05 As of 02/10/2021 05:59 PM ET
👍️0
Crusader Crusader 4 years ago
THIS is the sixth post

in 2021. Quiet board!

IT WILL NOT BE QUIET MUCH LONGER PER MY RESEARCH!

Of course I could be wrong! ??
👍️0
Crusader Crusader 4 years ago
TLSA looks to have lost a competitor,

in RLFLF... PR says LRFLF failed to meet 28 day survivability goal on Covid lung treatment.

Down over 40% today with billions of shares outstanding. Pain!

That just leaves a yet to be determined 60 day survivability clinical trial milepost.

TLSA will fare better, but it is a lesson learned.
👍️0

Your Recent History

Delayed Upgrade Clock